|1.||Carty, E: 3 articles (05/2002 - 06/2000)|
|2.||Rampton, D S: 3 articles (05/2002 - 06/2000)|
|3.||Lebel, Marcel: 2 articles (08/2004 - 03/2003)|
|4.||Moreau, Claudia: 2 articles (08/2004 - 03/2003)|
|5.||Larivière, Richard: 2 articles (08/2004 - 03/2003)|
|6.||Rodrigue, Marie-Eve: 2 articles (08/2004 - 03/2003)|
|7.||Lawrance, Ian Craig: 1 article (10/2010)|
|8.||Kulp, Werner: 1 article (01/2006)|
|9.||Greiner, Wolfgang: 1 article (01/2006)|
|10.||Gorenoi, Vitali: 1 article (01/2006)|
03/01/1995 - "Oral ridogrel may be a useful treatment for patients with non-severe ulcerative colitis, although specific indications require further studies."
01/01/2002 - "There was no clear indication in either trial of an effective dose of ridogrel in the treatment of ulcerative colitis."
01/01/2002 - "One US trial and one international trial were conducted to determine the effect of ridogrel on mild to severe active ulcerative colitis. "
05/01/2002 - "Preliminary reports suggest that ridogrel, a thromboxane synthase inhibitor, is anti-inflammatory and may have therapeutic benefits in patients with ulcerative colitis. "
01/01/2002 - "Oral ridogrel, from 5 mg once daily to 150 mg twice daily, improves the endoscopic appearance of colonic mucosa and clinical manifestations in mild to moderate ulcerative colitis. "
08/01/1991 - "However, such an occlusive thrombus formation was significantly reduced by combined TXA2 synthase/prostaglandin endoperoxide receptor inhibition (5 mg/kg i.v. ridogrel; time to occlusion greater than 300 minutes, n = 7; incidence of occlusion within 300 minutes, one of seven experiments; p less than 0.05). "
08/01/1991 - "This study reveals 1) a differential efficacy of TXA2 synthase inhibition, singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism, depending on the extent of the vessel wall lesion triggering thrombosis and the size of the thrombus required to obstruct the vascular lumen and 2) a significant synergism in preventing occlusive thrombosis of extensively damaged coronary arteries between strong TXA2 synthase inhibition and comparatively modest TXA2/prostaglandin endoperoxide receptor antagonism with ridogrel."
12/01/1992 - "Three hours after the formation of occlusive thrombus, animals were randomly assigned to receive one of the following: 1) t-PA (80 micrograms/kg + 8 micrograms.kg-1.min-1 i.v.) and saline; 2) t-PA and hirulog, a hirudin-based synthetic peptide and specific thrombin inhibitor (2 mg/kg + 2 mg.kg-1.hr-1 i.v.); 3) t-PA and ridogrel, a combined thromboxane A2 synthetase inhibitor and receptor antagonist (5 mg/kg + 2.5 mg.kg-1.hr-1 i.v.); or 4) t-PA, hirulog, and ridogrel. "
10/01/1990 - "30 min after thrombus formation, the animals received saline (controls, n = 10); SQ 29548 (0.4 mg/kg bolus + 0.4 mg/kg per h infusion), a TxA2/PGH2 receptor antagonist (n = 8); dazoxiben (5 mg/kg bolus + 5 mg/kg per h infusion), a TxA2 synthase inhibitor (n = 9); or R 68070 (5 mg/kg bolus + 5 mg/kg per h infusion), a drug that blocks TxA2/PGH2 receptors and inhibits TxA2 synthase (n = 8). "
08/01/1991 - "By contrast, occlusive thrombosis on deep vascular damage elicited by intraluminal stimulation (150-microA anodal constant current) in nonpreconstricted canine coronary arteries (time to occlusion, 237.1 +/- 13.9 minutes; n = 7; incidence of occlusion within 300 minutes, six of seven experiments) was not affected by platelet cyclooxygenase inhibition (5 mg/kg i.v. acetylsalicylic acid; n = 7), single TXA2 synthase inhibition (1.25 mg/kg i.v. ridogrel; n = 7), or single TXA2/prostaglandin endoperoxide receptor antagonism (10 mg/kg + 10 mg/kg/hr i.v. sulotroban for 300 minutes; n = 5). "
|3.||Crohn Disease (Crohn's Disease)
09/01/2001 - "A 5-mg dose of oral ridogrel was not more effective than placebo in inducing remission in patients with moderately active Crohn's disease. "
09/01/2001 - "To investigate the efficacy of ridogrel in patients with active Crohn's disease. "
09/01/2001 - "Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease."
09/01/2001 - "This was an international, multicentre, randomized, double-blind, placebo-controlled trial of 5 mg/day oral ridogrel for 12 weeks in 85 patients with moderately active Crohn's disease. "
|4.||Hypertension (High Blood Pressure)
08/01/1993 - "Short-term effects of ridogrel, a combined thromboxane synthase inhibitor and receptor antagonist, were investigated in 16 patients with uncomplicated essential hypertension. "
08/01/2004 - "To investigate the functional role of TXA2 in the progression of hypertension and renal failure, a group of uremic rats were treated with ridogrel (25 mg/kg/day), a TXA2 synthase inhibitor and receptor antagonist. "
03/01/2003 - "Both drugs were effective in preventing the progression of hypertension in rhEPO-treated rats although ABT-627 was more potent than ridogrel. "
08/01/1993 - "Thus, in patients with essential hypertension, acute administration of ridogrel reduces renal and extrarenal thromboxane A2 biosynthesis, increases renal and extrarenal prostacyclin biosynthesis, inhibits thromboxane receptor-activated platelet aggregation, but has no effect on systemic arterial pressure."
01/01/1990 - "It can be concluded that both ridogrel and forskolin afford protection against skin necrosis probably because of improved conditions in the microcirculation due to reduced platelet aggregation in the vasculature of the distal part of the flap."
06/01/2000 - "Ridogrel significantly reduced the release of thromboxane B2, but not prostaglandin E2 or tumour necrosis factor-alpha, from biopsies (P < 0.01 for 10 microM ridogrel). "
|1.||prostaglandin endoperoxide receptor
|2.||glucuronyl glucosamine glycan sulfate (Vessel)
|3.||Magnesium Sulfate (Sulfate, Magnesium)
|7.||Thromboxane A2 (A2, Thromboxane)
|9.||Aspirin (Acetylsalicylic Acid)
|10.||Prostaglandin H2 (PGH(2))